Anti-CEACAM5 antibodies and uses thereof

US11332542B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Pierre-Francois Berne · Paris, FR
• Francis Blanche · Paris, FR
• Herve Bouchard · Thiais, FR
• Beatrice Cameron · Paris, FR
• Tarik Dabdoubi · Paris, FR
• Stéphanie DECARY · Paris, FR
• Paul FERRARI · Paris, FR
• Alexey Rak · Paris, FR

Key dates

• Filing date: Sep 3, 2019
• Grant date: May 17, 2022
• Expiry date: May 31, 2040

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/70503
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.